Adaptimmune Therapeutics PLC Form 3 January 04, 2016

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

A Rawcliffe Adrian

(Last)

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Statement

(Month/Day/Year)

01/01/2016

Adaptimmune Therapeutics PLC [ADAP]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Chief Financial Officer

5. If Amendment, Date Original

Filed(Month/Day/Year)

440 SOUTH BROAD STREET, **UNIT 1803** 

(Street)

Director \_X\_\_ Officer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One Reporting Person

PHILADELPHIA, Â PAÂ 19146

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership

Table I - Non-Derivative Securities Beneficially Owned

Form: Direct (D)

(I) (Instr. 5) 4. Nature of Indirect Beneficial

Ownership (Instr. 5)

or Indirect

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of

5. Ownership Form of Ownership Derivative (Instr. 5)

6. Nature of Indirect Beneficial

Date Expiration Exercisable Date

Title

Amount or Number of Shares

Security: Derivative Security Direct (D)

or Indirect (I)

1

(Instr. 5)

Option to purchase Ordinary Shares

(1)

03/16/2025 Ordinary Shares

3,600,000 \$ 0.74 (2)

D

Â

# **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer

Other

Rawcliffe Adrian

440 SOUTH BROAD STREET, UNIT 1803 PHILADELPHIA, PAÂ 19146 Â

Â

Chief Financial Officer Â

# **Signatures**

/s/ Adrian George Rawcliffe Name: Adrian George Rawcliffe

01/04/2016

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Will be exercisable as to 900,000 Ordinary Shares on March 16, 2016 and will be exercisable as to the remainder ratably in monthly installments on the sixtheenth of each month from April 16, 2016 through March 16, 2019.
- The exercise price was converted from GBP0.50 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. (2) dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2